Early Stage

Blood testing device for early diagnosis of cancer and treatment monitoring

Blood testing device for early diagnosis of cancer and treatment monitoring


Raised this Round: Raised: $1,070,000

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type




SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap




Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



Laredo, Texas

Business Type


Delee, with a valuation cap of $10 million, is raising funds on Republic. The company has created a device, CytoCatch, for the early detection of circulating tumor cells in the bloodstream. The device also assists in the personalization and optimization of the treatment of patients and monitor the effectiveness of treatments. Thus, CytoCatch helps to increase the chances of curing cancer and survival. Delee was founded by Liza Velarde, Juan Felipe Yee, and Alejandro Abarca in November 2016 and has already raised over $1.3 million in funding since its inception. The current round of crowdfunding has a minimum goal of $75,000 and a maximum goal of $1,070,000. Delee already has a fully functional technology that is being tested for prostate cancer.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 12/10/2019
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Delee 12/15/2022 Republic $22,000,000 $204,059 SAFE Funded RegCF
Delee 04/05/2022 StartEngine $22,040,057 $347,498 Equity - Preferred Funded RegCF
Delee 04/23/2020 Republic $10,000,000 $1,070,000 SAFE Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article


Delee has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected into the top 10%-20% of our due diligence funnel. If you have questions regarding our deal diligence and selection methodology, please reach out to

Next Section: Problem


While there have been significant advances in treating cancer, it is forecasted that cancer rates will increase by more than 50% and death rates will almost double in the next twenty years. Currently, cancer screening is available for specific forms of cancer such as breast, colon, prostate, lung, and others. These tests can only detect the cancer once it has formed in the body and begun to take hold. They do so by imaging a specific area, which requires significant human touch to identify, gather, and assess. Additionally, cancer tests are expensive and generally not ordered unless there is a known risk. 

Advances in cancer treatment have dramatically reduced the number of fatalities, but the key to this is early detection. The earlier the cancer is detected the higher the probability of beating it.

It is widely believed that cancer can begin developing in the body as early as 12 years before clinical symptoms appear. What if there were a simple blood test that could detect cancer when it was at the minute cellular level before it caused any problems?

Next Section: Solution


Delee has created CrytoCatch, which uses a blood sample to detect 1 tumor cell out of 37.5 billion blood cells. This small machine initiates a rapid process in as little as 15 minutes to isolate a single tumor cell, thus identifying the start of cancer unimaginably early.

How is this possible?

In the majority of cancers, when a tumor develops, even if it is still localized, it releases malignant cells into the bloodstream, called circulating tumor cells (CTC). These cells have a key role in the establishment of metastasis in other organs.

Next Section: Other


CytoCatch is on track to be the second FDA approved CTC test by 2023. It will be the first for early detection of cancer, and it will provide valuable feedback for increasing the efficacy of cancer treatments. Prior to FDA clearance, CytoCatch will be marketed as a powerful research tool for pharmaceutical companies and researchers to improve their cancer treatment research.  

Next Section: Other


CTC, the core technology in CytoCatch, was first given Current Procedural Technology codes at the beginning of 2013. Those codes are necessary to bill Medicare and insurance companies. CellSearch received FDA approval for its CTC technology in 2004 for monitoring metastatic breast cancer. It has gained further FDA approval for monitoring very specific cancer treatments. CellSearch, like the majority of CTC research, is used to evaluate the progress of a patient’s cancer treatment. This technology enables a more comprehensive assessment of whether the cancer is shrinking or growing after the cancer has been identified through clinical symptoms.  

Currently, CellSearch remains the only FDA approved CTC product on the market. There is no indication of a direct competitor to CytoCatch, which is focused on identifying cancer long before any known test.

Next Section: Other


Liza Velarde, CEO, and Co-Founder – Ms. Velarde’s charisma leaps through the phone. She has a passion for her company and is quick to identify gaps she and her co-founders have and how she has been able to access experts to fill those gaps. 

She started Delee while finishing her degree summa cum laude at Tecnologico de Monterrey. According to Delee’s marketing, Ms. Velarde is responsible for creating the company’s relationships with hospitals and research institutions. She was awarded the prestigious Cartier Women’s Initiative Award and the WeXchange. In 2019, she also co-founded Zen Fluidics, a line of products to empower researchers to develop unique microfluid applications.

Next Section: Why We Like it

Why We Like it

  • Model: Delee is uniquely positioned for revenue pre-FDA and post-FDA approval. The post-FDA approval is the most lucrative part of Delee’s business model, but it is noteworthy for Delee’s innovation to have revenue before FDA approval.
    • Delee will sell the CytoCatch machine to researchers prior to FDA approval. In addition to the sales price of the machine, Delee will gain revenues via sales of the necessary reagents and consumables to perform each test.
  • Market Gap: Delee’s strategy is to attack cancer detection before there are any clinical symptoms. This innovation is a market gap many do not have the imagination to pursue. Further, Delee intends to begin testing for prostate cancer first. This focus will be a significant step in cancer treatment because, according to Ms. Velarde, women’s cancer is currently the only one with an early detection test. Providing a male cancer screening will be a significant step for male cancer treatment and will further differentiate Delee’s product.
  • Clinical Trials: To save money on costly clinical trials, trials will be conducted in Monterrey, Mexico. Delee will pursue United States FDA approval but all testing and engineering will occur in Mexico, allowing significant cost savings.

Next Section: Other

The Rating: Deal To Watch

“Cancer is curable, the problem is the lack of timely information.” – Ms. Velarde 

Ms. Velarde has the type of drive and vision to realize the seemingly impossible with CytoCatch. While she was still at University, during an elevator ride, she pitched Delee to the Heineken CEO Jean-Francois van Boxmeer and convinced him to donate funds to the first prototype.

The Delee team is using an almost twenty-year-old technology, CTC, which never gained the expected promise with still only one FDA approved product in the market. While cancer treatment is a very crowded market, diagnosis before clinical symptoms is not. This young, energetic team might just have the formula to radically change cancer.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Delee on Republic
Platform: Republic
Security Type: SAFE
Valuation: $10,000,000

Follow company

Follow Delee on Republic

Buy Delee 's Deal Report

Warning: according to the close date for this deal, Delee may no longer be accepting investments.

Delee Deal Report

Get KingsCrowd’s comprehensive report on Delee including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Delee is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Delee deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge